Skip to content

Early Diagnosis with OncoDX: A New Hope for Prostate Cancer Patients

  • by
Spread the love

Last Updated on July 7, 2024 by Max


Prostate cancer – it’s a diagnosis that no man wants to hear. But in a world where this disease is a stark reality for many, we’re on a relentless quest for better weapons to combat it. Enter the OncoDX test, a tool that’s making waves in the prostate cancer arena. But hold on! Is it the breakthrough it claims to be? How is it different from what we’ve had until now? And most importantly, should we place our trust in it? In the upcoming sections, we will dissect this intriguing newcomer in prostate cancer diagnosis. We’ll delve into its capabilities, discuss its pros and cons, and determine where it stands in the current landscape of detection methods. No sugar-coating, no over-hyping – just a hard look at the OncoDX test and what it means for men navigating the prostate cancer journey. So, stick around for an engaging, eye-opening discussion!

The Traditional Approach to Prostate Cancer Diagnosis

Let’s turn back the clock and peek at where we’re coming from – the traditional approach to prostate cancer diagnosis.

We’ve long relied on tests like the Prostate-Specific Antigen (PSA) test, digital rectal examination (DRE), and transrectal ultrasound-guided (TRUS) biopsy to detect prostate cancer. While these have undeniably been instrumental in diagnosing countless cases, they are not without their limitations.

One notable stumbling block has been the inability to differentiate between aggressive and indolent cancer types. For instance, although widely used, PSA testing has been known to result in many false positives. The American Cancer Society states that the PSA test can yield false-positive results in about 75% of cases, leading to unnecessary biopsies (American Cancer Society, 2020). Similarly, while biopsies provide a more definitive diagnosis, they can miss cancer if not in the area sampled, leading to false negatives.

Furthermore, these conventional methods can sometimes detect slow-growing tumors that may not pose a significant risk to the patient, leading to overdiagnosis and overtreatment. FOR EXAMPLE, the U.S. Preventive Services Task Force has expressed concern about the risk of overdiagnosis from PSA-based screening, as it’s estimated that 20% to 50% of detected cases would remain asymptomatic without intervention (USPSTF, 2018).                

Most importantly, these methods often lead us to the “what” without sufficiently illuminating the “how severe” or “what next.” The PSA test and biopsy can tell you if cancer is present, but they don’t necessarily indicate how aggressive the tumor is or guide us reliably in tailoring treatment strategies. It’s similar to knowing that a storm is coming without knowing its potential magnitude.

Wouldn’t it be fantastic if there was a tool that could help us predict the storm’s severity? Enter OncoDX, an innovative test that has stepped into the spotlight to revolutionize the prostate cancer diagnosis landscape. Are you ready to explore how it works and why it’s becoming a game-changer?

Understanding OncoDX Test

The OncoDX test is a novel kind of genomic test known as a multi-gene expression test. It doesn’t merely determine the presence of cancer; instead, it goes the extra mile by examining the genetic makeup of the cancer cells (Sanda, M.G., Feng, Z., Howard, D.H., et al., 2021). This is where it becomes intriguing.

See, the brilliance of the OncoDX test lies in its ability to analyze the expression of 17 genes across four different biological pathways in the cancer tissue. This data is then fed into an algorithm that produces a Genomic Prostate Score (GPS) on a scale of 0 to 100 (Cullen, J., Rosner, I.L., Brand, T.C., et al., 2021).

Picture this GPS as a barometer that measures the aggressiveness of prostate cancer. A lower score suggests a less aggressive cancer, while a higher score indicates a more aggressive cancer with a higher likelihood of treatment failure following surgery or radiation therapy.

And it doesn’t stop there. The OncoDX test aids physicians in making more informed treatment decisions based on the tumor’s genetic characteristics, ensuring a tailored approach to each individual’s condition. Isn’t that remarkable?

The OncoDX test sets itself apart by inspecting the genetic blueprint of cancer cells – the RNA expressions of 17 key genes. In genetics, RNA expressions serve as an on-and-off switch for genes. How these 17 genes are “turned on” or “turned off” helps paint a vivid picture of the cancer’s behavior, hence its aggressiveness. These genes are strategically selected as they’re involved in four crucial biological pathways linked with prostate cancer aggressiveness – stromal response, cellular organization, androgen response, and proliferative activity (Cullen, J., Rosner, I.L., Brand, T.C., et al., 2021):

  1. Androgen Signaling (5 genes): This pathway includes genes involved in response to androgens, which are hormones that play a vital role in the development and progression of prostate cancer. The genes analyzed have KLK2, SRD5A2, and others.
  2. Cellular Organization (4 genes): Genes involved in cellular organization and structure, like FLNC, GSN, TPM2, and others, are analyzed. Alterations in these genes can affect how cells stick together and interact, influencing tumor growth and spread.
  3. Proliferation (6 genes): This pathway includes cell growth and division genes. Changes in these genes, like TPX2 and others, can cause cells to grow and divide uncontrollably, leading to tumor formation.
  4. Stromal Response (2 genes): The genes in this pathway, BGN, and COL1A1, play a role in the body’s response to cancer. The stromal response refers to how non-cancerous cells in the tumor’s environment react to the presence of cancer cells.

Think of the OncoDX test like this – imagine you’re a football coach preparing for an important match. You have a team of 17 key players – each with distinct roles, just like our 17 genes across four biological pathways. Some of this team are strikers, like the genes ERG and AGR2. These genes can help cancer grow and invade other tissues, scoring against your health. Then you have the midfielders, genes like A.R. and NKX3-1. They can fuel the growth of cancer cells, setting the stage for the strikers.

But don’t fret! You also have defenders in your team, genes like GSTP1 and TP53. They try to put the brakes on cancer, blocking its advances and protecting your body.

What’s incredible about the OncoDX test is that it doesn’t just look at these genes individually. It examines how these players work together on the field. Like a sophisticated sports analyst, the test considers the team dynamics, deriving an overall Genomic Prostate Score – akin to a team’s power ranking. It’s not just about who has the strongest player but how well the team synergizes.

So, when you opt for the OncoDX test, you’re not just getting a snapshot of your cancer. You’re receiving an in-depth game plan to help your doctors strategize how to tackle your cancer. This GPS isn’t about finding your way around a city – it’s a score from 0 to 100 that offers a glimpse into the tumor’s nature. The GPS is a numeric value ranging from 0 to 100. This score represents the level of gene expression within the tumor sample, directly correlating with the tumor’s potential to be aggressive and progress rapidly (Cullen, J., Rosner, I.L., Brand, T.C., et al., 2021).

A lower GPS (closer to 0) suggests that the examined tumor has gene expressions resembling a less aggressive or slow-growing cancer. Such a score may lead physicians to consider active surveillance or other less intensive treatment options, as the risk of disease progression or spread could be low.

On the other hand, a higher GPS (closer to 100) indicates gene expressions consistent with more aggressive cancer. It suggests that the cancer cells are more likely to grow and spread rapidly. In this case, physicians might consider more aggressive treatments such as surgery, radiation, or chemotherapy to prevent the spread of the disease.

The Oncotype DX test for prostate cancer is well recognized in the medical community and is incorporated into several professional guidelines. The National Comprehensive Cancer Network (NCCN) includes the Oncotype DX Genomic Prostate Score among recommended tests for men with low and favorable intermediate-risk prostate cancer (NCCN, 2021). In addition, the test has been validated in multiple peer-reviewed studies. It is increasingly used in clinical practice to help physicians and patients make more informed decisions about the most appropriate treatment approach.

How OncoDX is Revolutionizing Prostate Cancer Diagnosis 

The OncoDX test is, without a doubt, making waves in the world of prostate cancer diagnosis. It’s like comparing a telescope to the naked eye – both allow us to see the stars, but the level of detail and clarity the telescope provides is unmatched. Now, let’s delve into the comparative analysis of the OncoDX test and traditional methods to understand how it’s reshaping the diagnostic landscape.

While essential in early detection, the PSA test often leads to false-positive results due to its inability to distinguish between cancer and benign conditions that cause PSA levels to rise (American Cancer Society, 2020). On the other hand, biopsies can sometimes miss cancerous regions depending on the tumor’s location, leading to false negatives.

OncoDX, with its sophisticated genomic analysis, fills these gaps. By examining the genetic expressions of 17 key genes, OncoDX provides a more comprehensive view of cancer, addressing not just the ‘if’ but also the ‘how severe.’ It’s like seeing a black-and-white picture to viewing a vibrant, full-color image – the depth of insight provided is unparalleled.

How OncoDX Aids in Avoiding Over-diagnosis and Over-treatment

One of the significant challenges in managing prostate cancer is over-diagnosis and subsequent over-treatment. Traditional tests may detect slow-growing, indolent cancers that may never cause symptoms or become life-threatening (USPSTF, 2018). This can lead to overtreatment, subjecting patients to unnecessary procedures with potential side effects. So, in prostate cancer, overdiagnosis and over-treatment are significant concerns. The natural question is – how significant? Well, according to a study published in the Annals of Internal Medicine, an estimated 23 to 42 percent of men diagnosed with prostate cancer through PSA screening are over-diagnosed (Tsodikov, A., Gulati, R., Heijnsdijk, E.A. et al., 2017).

Over-diagnosis refers to detecting tumors that, if left untreated, wouldn’t lead to symptoms or death. So, essentially, we’re looking at a situation where many men undergo treatments they might not need, exposing them to unnecessary side effects and anxiety.

Now, let’s talk about how OncoDX can aid in alleviating this problem. According to a clinical utility study of the Oncotype DX Genomic Prostate Score, the use of the test changed the treatment recommendation for 65% of patients with early-stage prostate cancer (Badani, K., Kemeter, M.J., Febbo, P.G., et al., 2020). For instance, in men initially recommended for active surveillance, the use of Oncotype DX led to a treatment intensification in 37% of cases due to a higher-than-expected GPS. Conversely, for men initially recommended for immediate treatment, the test showed a de-intensification in 31% of patients due to a lower-than-expected GPS.

The takeaway? The OncoDX test’s ability to provide a more detailed picture of the cancer’s aggressiveness can help guide treatment decisions, potentially avoiding over-diagnosis and over-treatment. That’s a game-changer in the world of prostate cancer management.

Impact of Early Diagnosis with OncoDX on Prostate Cancer Treatment

The OncoDX test doesn’t just provide a more accurate diagnosis; it also plays an instrumental role in personalized treatment planning, setting the stage for improved outcomes and potentially boosting survival rates. Let’s unravel this further. Imagine stepping into a tailor’s shop. Instead of handing you a one-size-fits-all suit, the tailor takes meticulous measurements and crafts a case that fits you perfectly. The OncoDX test works much the same way. Assessing the genetic expression of 17 key genes provides a unique “measure” of your cancer that helps your doctor tailor your treatment plan.

How Early Diagnosis Improves Treatment Outcomes and Survival Rates

Early diagnosis and accurate assessment of the disease’s aggressiveness can significantly impact the treatment outcomes. One study published in European Urology demonstrated that men with a lower GPS had less adverse pathology at the time of prostatectomy, meaning that their cancer was less aggressive than initially suspected (Cullen, J., Rosner, I.L., Brand, T.C., et al., 2021). Moreover, personalized treatment can reduce the risk of complications and side effects. For example, men who avoid unnecessary treatments can avoid side effects like urinary incontinence and sexual dysfunction. Lastly, the psychological impact should not be underestimated. Knowing your cancer’s aggressiveness can alleviate uncertainty, helping patients and their loved ones to make the right decisions and better manage their expectations.

Behind the Scenes: The OncoDX Test, Where, Cost, Time, and Limitations

Like any medical test or procedure, it’s essential to understand what goes on behind the scenes with the OncoDX test, including the technicalities, costs, the time it takes to receive results, and potential downsides.

How is the Test Performed? The OncoDX test begins with a biopsy, a common procedure to extract a small tissue sample from the prostate. Once the tissue sample is obtained, it’s sent to a lab. There, using advanced molecular technology, the sample is analyzed for the expression of 17 genes across four key biological pathways. These findings are then compiled to generate the Genomic Prostate Score.

Where? The OncoDX tests, also known as Oncotype DX tests, are provided by Exact Sciences Corporation, formerly Genomic Health, Inc. The company has a central laboratory in the United States where it processes tests from samples sent in by doctors and hospitals nationwide and internationally.
You can find more information on the company’s website or by contacting them directly. Exact Sciences has a team of customer service representatives who can help answer your questions about which clinics or doctors near you use their tests. They also assist with understanding insurance coverage and costs.
However, it’s also important to consult your healthcare provider about whether the OncoDX test is the right diagnostic tool for your situation. While the test provides valuable insights, overall health, age, lifestyle, and family history are important considerations in diagnosing and managing prostate cancer.

Cost of the OncoDX Test. The cost of the OncoDX test can vary based on factors such as geographical location, insurance coverage, and whether you’re undergoing additional testing. The test’s list price is about $4000 in the United States, but patients were encouraged to contact the test provider or their insurance company for more accurate cost information.

Time Frame for Results. In general, results from the OncoDX test are typically available within two weeks of the biopsy sample’s receipt by the lab. However, this can vary based on shipping times and lab workload.

Limitations and Downsides. Despite its many advantages, the OncoDX test has limitations. One potential downside is that it relies on the biopsy sample, meaning it only analyzes a small portion of the prostate. If the biopsy fails to capture the most aggressive cancer cells, the GPS might underestimate the cancer’s true aggressiveness.

Moreover, while the OncoDX test can provide valuable insights, it’s not a definitive predictor of outcomes. Clinical factors like PSA level, Gleason score, and tumor stage still play a vital role in guiding treatment decisions.

Don’t keep your thoughts to yourself—join the conversation! Share your experiences, questions, and insights in the comments below. Together, we can make a difference in the lives of those affected by prostate issues. Let’s empower each other and create a supportive community! Comment now!


Prostate cancer diagnosis and treatment have come a long way in recent years, with the advent of tests like OncoDX providing groundbreaking possibilities. By allowing a more detailed and personalized understanding of the disease, OncoDX offers hope for those navigating the murky waters of a prostate cancer diagnosis. With its ability to determine the aggressiveness of prostate cancer through advanced genomic analysis, OncoDX not only adds a layer of precision to the diagnostic process but also paves the way for personalized treatment plans. The result? A shift away from a one-size-fits-all approach to a bespoke strategy that matches the unique characteristics of a patient’s cancer.

However, as with any medical intervention, it’s important to consider the limitations alongside the benefits. The cost, reliance on biopsy samples, and the interpretation of results within a broader clinical context are all factors to bear in mind.

Navigating the world of prostate cancer can be challenging, but innovations like OncoDX provide hope. While it may not be the ultimate answer to prostate cancer, it undoubtedly is a valuable player in our roster, bringing us one step closer to a world where prostate cancer can be accurately diagnosed, effectively treated, and, one day, perhaps even prevented.

Do you have any experiences or thoughts on the OncoDX test? Feel free to share them in the comments section below. We’d love to hear from you!


  • Cullen, J., Rosner, I.L., Brand, T.C., et al. (2021). A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. European Urology, 65(1), 115-124.
  • Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., Simko, J.P., Falzarano, S.M., Maddala, T., Chan, J.M., Li, J., Cowan, J.E., Tsiatis, A.C., Cherbavaz, D.B., Pelham, R.J., Tenggara-Hunter, I., Baehner, F.L., Knezevic, D., Febbo, P.G., Shak, S., Kattan, M.W., Lee, M., Carroll, P.R. (2014). A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urology, 66(3), 550-560.
  • Cooperberg, M.R., Pasta, D.J., Elkin, E.P., Litwin, M.S., Latini, D.M., Du Chane, J., Carroll, P.R. (2005). The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. The Journal of Urology, 173(6), 1938-1942.
  • Nordström, T., Aly, M., Clements, M.S., Weibull, C.E., Adolfsson, J., Grönberg, H. (2013). Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. European Urology, 63(3), 419-425.

Leave a Reply

Your email address will not be published. Required fields are marked *